MIRM Q3 2024 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$90M+89.4% YoY

Gross Profit

$70M77.0% margin

Operating Income

-$13M-14.0% margin

Net Income

-$14M-15.8% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+16.1%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

-$6M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$668M

Total Liabilities

$436M

Stockholders' Equity

$232M

Cash & Equivalents

$223M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$90M	$48M	+89.4%
Gross Profit	$70M	$37M	+85.5%
Operating Income	-$13M	-$25M	+49.6%
Net Income	-$14M	-$24M	+39.7%

Revenue Segments

Product

$90M100%

License and Other Revenue

$75,0000%

Geographic Segments

UNITED STATES

$74M82%

Rest Of World

$16M18%